Health Care • Industrial Specialties
$179.16 ▲ +2.00
(+1.13%)
MKT CAP: $6.91B • VOL: 182.4K
52W L $151 52W H $209
MSA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.87B | $1.81B | $1.79B |
| YoY Revenue Growth % | +3.7% | +1.1% | — |
| Gross Profit | $871.1M | $860.4M | $786.6M |
| Gross Margin % | 46.5% | 47.6% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $371.8M | $389.2M | $231.3M |
| Operating Margin % | 19.8% | 21.5% | 12.9% |
| Net Income (GAAP) | $278.9M | $285.0M | $58.6M |
| EBITDA (Normalized) | $426.6M | $432.6M | $295.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $363.9M | $296.4M | $92.9M |
| Capital Expenditures (CapEx) | $68.4M | $54.2M | $80.4M |
| Free Cash Flow (FCF) | $295.4M | $242.2M | $12.4M |
| FCF Margin % | 15.8% | 13.4% | 0.7% |
| Return on Invested Capital (ROIC %) | 16.6% | 21.1% | 8.0% |
| Cash & Short-Term Equivalents | $165.1M | $164.6M | $418.2M |
| Total Debt (Short + Long Term) | $572.7M | $481.6M | $889.5M |
| Total Stockholders' Equity | $1.37B | $1.14B | $1.82B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MSA.